[1] |
Milsom I, Coyne KS, Nicholson S, et al. Global prevalence and economic burden of urgency urinary incontinence: a systematic review[J]. Eur Urol, 2014, 65(1): 79-95.
|
[2] |
初磊,王建军,樊伯珍,等.上海市成年女性尿失禁的流行病学研究[J].现代妇产科进展,2015,27(6):421-424.
|
[3] |
Lu S, Zhang H, Zhang Y, et al. Prevalence and risk factors of urinary incontinence among perimenopausal women in Wuhan[J]. J Huazhong Univ Sci Technolog Med Sci, 2016, 36(5): 723-726.
|
[4] |
Amundsen CL, Richter HE, Menefee SA, et al. Onabotulinumtoxin A vs sacral neuromodulation on refractory urgency urinary incontinence in women[J]. JAMA, 2015, Epub.
|
[5] |
Caraway NP, Katz RL. A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis[J]. Cancer Cytopathol, 2010, 118(4): 175-183.
|
[6] |
Sakakibara R, Tsunoyama K, Takahashi O, et al. Real-time measurement of oxyhemoglobin concentration changes in the frontal micturition area: an fNIRS study[J]. Neurourol Urodynam, 2010, 29(5): 757-764.
|
[7] |
Fowler CJ, Griffiths DJ. A decade of functional brain imaging applied to bladder control[J]. Neurourol Urodyn, 2009, 29(1): 49-55.
|
[8] |
Compérat E, Reitz A, Delcourt A, et al. Histologic Features in the urinary bladder wall affected from neurogenic overactivity-a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A[J]. Eur Urol, 2006,50(5): 1058-1064.
|
[9] |
Karstens L, Asquith M, Davin S, et al. Does the urinary microbiome play a role in urgency urinary incontinence and its severity[J]? Front Cell Infect Microbiol, 2015, Epub.
|
[10] |
Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus[J]. Urol Int, 2015, 94(1): 1-24.
|
[11] |
Tse V, King J, Dowling C, et al. Conjoint urological society of Australia and New Zealand(USANZ) and urogynaecological society of Australasia(UGSA) guidelines on the management of adult non-neurogenic overactive bladder[J]. Bju Int, 2016, 117(1): 34-47.
|
[12] |
Sherburn M, Bird M, Carey M, et al. Incontinence improves in older women after intensive pelvic floor muscle training: An assessor-blinded randomized controlled trial[J]. Neurourol Urodyn, 2011, 30(3): 317-324.
|
[13] |
Schreiner L, Santos TG, Souza AB, et al. Electrical stimulation for urinary incontinence in women: a systematic review[J]. Int Braz J Urol, 2013, 39(4): 454-464.
|
[14] |
Herderschee R, Hay-Smith EJ, Herbison GP, et al. Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women[J]. Cochrane Database Syst Rev, 2011, 7: CD009252.
|
[15] |
Olivera CK, Meriwether K, El-Nashar S, et al. Nonantimuscarinic treatment for overactive bladder: a systematic review[J].Am J Obstet Gynecol, 2016, 215(1): 34-57.
|
[16] |
Gibson W, Athanasopoulos A, Goldman H, et al. Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence[J]? Int J Clin Pract, 2014, 68(9): 1165-1173.
|
[17] |
Wagg A. Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder[J]. Res Rep Urol, 2012, 4: 57-64.
|
[18] |
Aziminekoo E, Ghanbari Z, Hashemi S, et al. Oxybutynin and tolterodine in a trial for treatment of overactive bladder in Iranian women[J]. J Family Reprod Health, 2014, 8(2): 73-76.
|
[19] |
Singh-Franco D, Machado C, Tuteja S, et al. Trospium chloride for the treatment of overactive bladder with urge incontinence[J]. Clin Ther, 2005, 27(5): 511-530.
|
[20] |
Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin[J]. Int J Clin Pract, 2008, 62(11):1792-1800.
|
[21] |
Vij M, Drake MJ. Clinical use of theβ3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome[J]. Ther Adv Urol, 2015, 7(5): 241-248.
|
[22] |
Guo C, Yang B, Gu W, et al. Intravesical resiniferatoxin for the treatment of storage lower urinary tract symptoms in patients with either interstitial cystitis or detrusor overactivity: a meta- analysis[J]. PLoS One, 2013, 8(12): e82591.
|
[23] |
Lazzeri M, Spinelli M, Zanollo A, et al. Intravesical vanilloids and neurogenic incontinence: ten years experience[J]. Urol Int, 2004, 72(2): 145-149.
|
[24] |
Kuo H, Liu H, Chuang Y, et al. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study[J]. Eur Urol, 2014, 65(6): 1117-1124.
|
[25] |
Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review[J].J Urol, 2006, 175(3 PT 1): 835-841.
|
[26] |
卫中庆.电刺激/调节技术在神经源性膀胱尿道功能障碍的临床应用[J].中华临床医师杂志(电子版),2012,6(13):24-27.
|
[27] |
Finazzi-AgròE, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial[J].J Urol, 2010, 184(5): 2001-2006.
|